roxadustat

Phase 3Completed
0 watching 0 views this week๐Ÿ“ˆ Rising
77
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hemodialysis Patients With Renal Anemia

Conditions

Hemodialysis Patients With Renal Anemia

Trial Timeline

May 16, 2016 โ†’ Nov 28, 2017

About roxadustat

roxadustat is a phase 3 stage product being developed by Astellas Pharma for Hemodialysis Patients With Renal Anemia. The current trial status is completed. This product is registered under clinical trial identifier NCT02779764. Target conditions include Hemodialysis Patients With Renal Anemia.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (12)

NCT IDPhaseStatus
NCT05970172Phase 3Recruiting
NCT04408820Pre-clinicalCompleted
NCT04076943Phase 2Completed
NCT03960489Phase 1Completed
NCT02964936Phase 3Completed
NCT02965040Phase 1Completed
NCT02780726Phase 3Completed
NCT02780141Phase 3Completed
NCT02779764Phase 3Completed
NCT01630889Phase 2Completed
NCT01244763Phase 2Completed
NCT01083888Phase 1Completed

Competing Products

20 competing products in Hemodialysis Patients With Renal Anemia

See all competitors
ProductCompanyStageHype Score
R744 + R744 + rHuEPO + rHuEPO + R744 placebo + rHuEPO placeboChugai PharmaceuticalPhase 3
77
R744 + R744Chugai PharmaceuticalPhase 3
77
R744Chugai PharmaceuticalPhase 3
77
ASP7991Astellas PharmaPhase 1
33
roxadustat + Darbepoetin alfaAstellas PharmaPhase 3
77
roxadustatAstellas PharmaPhase 3
77
ASP1585Astellas PharmaPhase 2
52
Kiklin capsulesAstellas PharmaPre-clinical
23
DoravirineMerckApproved
85
BPS804 + PlaceboNovartisPhase 2
52
PA21 + Sevelamer hydrochlorideKissei PharmaceuticalPhase 3
76
PA21 + PA21 + PA21 + PA21 + PlaceboKissei PharmaceuticalPhase 2
51
PA21Kissei PharmaceuticalPhase 3
76
PA21Kissei PharmaceuticalPhase 3
76
[ยนโดC]EtelcalcetideAmgenPhase 1
32
Epoetin HospiraPfizerPhase 3
76
Epoetin HospiraPfizerPhase 3
76
sodium thiosulfateSanofiPre-clinical
22
EnoxaparineSanofiApproved
84
Alirocumab 150 MG/ML [Praluent]Regeneron PharmaceuticalsPhase 3
76